Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals. 29 Mar, 2022 | 10:09h | UTC Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals – UK Health Security Agency Related: Myocarditis following a third Pfizer vaccination dose in military recruits in Israel. Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. [Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy. Myocarditis after BNT162b2 vaccination in Israeli adolescents. Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021. A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine. [Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection. Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms. Heart-inflammation risk from Pfizer COVID vaccine is very low. Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons. Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients. Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.